The binary catalyst is topline data by end of 2026. ALS is a large unmet-need market with no cure; positive CAFS data would likely drive significant upside for this single-asset-stage biotech. Negative data would be severely bearish. No interim data or safety signals were disclosed — the stock will trade on sentiment and ALS pipeline speculation until data readout.
Price Chart
Executive Summary
MediciNova announced completion of the last patient's final visit in the double-blind portion of its Phase 2b/3 COMBAT-ALS trial evaluating MN-166 (ibudilast) for ALS. Topline results from the double-blind portion are expected by end of 2026, with the full study LPLV (including open-label extension) expected in March 2027. This is a binary catalyst event — positive data could validate MN-166's neuroinflammation mechanism and open a large ALS market, while negative data would severely impair the pipeline.
Key Facts
- Last patient, last visit (LPLV) completed in double-blind portion of Phase 2b/3 COMBAT-ALS trial
- 234 participants randomized to two treatment arms at US and Canadian sites
- Topline results from double-blind portion expected by end of 2026
- Full study LPLV (including open-label extension) expected March 2027
- Primary endpoint: Combined Assessment of Function and Survival (CAFS)
- MN-166 has FDA Fast Track and Orphan Drug designations for ALS, plus EMA orphan designation
- MN-166 is MediciNova's lead asset; ALS is a high-unmet-need indication
Financial Impact
Not stated — no revenue or financial data in release. MediciNova is a clinical-stage biopharma with no approved products.
Risk Factors
- Topline data could be negative or fail to meet primary endpoint, severely impairing pipeline value
- ALS trials have high failure rates historically
- No partner or funding commitments disclosed for further development
- Small sample size (234 patients) may limit statistical power
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3368112 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 29d ago | Press Release | $2.10 $1.40 | ▼ −33.33% | ▼ −33.30% | $1.41 (−32.86%) |
Sep 24, 2026 4w ago | Press Release | $2.65 $1.41 | ▼ −46.79% | ▼ −46.37% | $1.41 (−46.79%) |
Sep 2, 2026 7w ago | 8-K | $1.43 $1.68 | ▲ +17.48% | ▲ +17.57% | $1.41 (−1.40%) |
Aug 19, 2026 9w ago | 8-K | $1.38 $3.45 | ▲ +150.00% | ▲ +151.95% | $1.41 (+2.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers